Journal
EXPERT REVIEW OF HEMATOLOGY
Volume 2, Issue 6, Pages 663-672Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1586/EHM.09.53
Keywords
acute myeloid leukemia; AML; leukemia stem cell; minimal residual disease
Categories
Funding
- NIH HHS [DP2 OD007399] Funding Source: Medline
Ask authors/readers for more resources
Most adult patients with acute myeloid leukemia (AML) die from their disease. Relapses are frequent even after aggressive multiagent chemotherapy and allogeneic stem cell transplantation. AML is a biologically heterogeneous disease, characterized by frequent cytogenetic abnormalities and an increasing spectrum of genetic mutations and molecular aberrations. Laboratory data suggest that AML originates from a rare population of cells, termed leukemic stem cells (LSCs) or leukemia-initiating cells, which are capable of self-renewal, proliferation and differentiation. These cells may persist after treatment and are probably responsible for disease relapse. This review will describe bench and translational research in LSCs and discuss how the data should be used to change the direction of developmental therapeutics and clinical trials in AML.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available